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Abstract: Cardiovascular diseases, including coronary artery disease, ischemic heart diseases such
as acute myocardial infarction and postischemic heart failure, heart failure of other etiologies,
and cardiac arrhythmias, belong to the leading causes of death. Activation of capsaicin-sensitive
sensory nerves by the transient receptor potential vanilloid 1 (TRPV1) capsaicin receptor and other
receptors, as well as neuropeptide mediators released from them upon stimulation, play important
physiological regulatory roles. Capsaicin-sensitive sensory nerves also contribute to the development
and progression of some cardiac diseases, as well as to mechanisms of endogenous stress adaptation
leading to cardioprotection. In this review, we summarize the role of capsaicin-sensitive afferents and
the TRPV1 ion channel in physiological and pathophysiological functions of the heart based mainly
on experimental results and show their diagnostic or therapeutic potentials. Although the actions of
several other channels or receptors expressed on cardiac sensory afferents and the effects of TRPV1
channel activation on different non-neural cell types in the heart are not precisely known, most data
suggest that stimulation of the TRPV1-expressing sensory nerves or stimulation/overexpression of
TRPV1 channels have beneficial effects in cardiac diseases.
Keywords: acute myocardial infarction; arrhythmia; atherosclerosis; capsaicin; cardioprotection;
ischemic heart disease; heart failure; transient receptor potential vanilloid type 1 (TRPV1) receptor
1. Introduction and Background
Capsaicin is the active, pungent component of chili peppers (characterized by Scoville Heat
Units, SHU, 15–16 million SHU for pure capsaicin) that is able to selectively activate and, after high
dose administration, selectively defunctionalize an important subpopulation of sensory neurons with
thinly myelinated Aδ or unmyelinated C fibers [1]. The actions of capsaicin are mediated through the
activation of the transient receptor potential vanilloid type 1 receptor (TRPV1), formerly known as the
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vanilloid receptor 1 (VR1) or the capsaicin receptor [2,3], expressed predominantly but not exclusively
(see below) on these chemosensitive peptidergic sensory nerves. Resiniferatoxin (RTX) is an efficient
activator for TRPV1 receptors, approximately 1000 times more potent than capsaicin (with an SHU of
16 billion!), which results in activation of primary sensory neurons, [4] and repeatedly administered
high doses induce ultrastructural alterations and neuropeptide depletion from these nerves similarly
to capsaicin [5]. Anatomical and functional evidence indicate that capsaicin-sensitive primary afferent
neurons of both spinal (thoracic dorsal root ganglia) and vagal (nodose ganglion) origin innervate the
heart [6–8].
The incidence of cardiovascular diseases is continuously rising worldwide [9]. Ischemic heart
diseases including coronary artery disease due to atherosclerotic burden, acute myocardial infarction,
postischemic heart failure, and heart failure of different etiologies belong to the leading causes of
death in the industrialized world [10]. In the last decades, experimental and clinical studies have
identified an essential role of cardiac sensory nerves, including the capsaicin-sensitive fibers in cardiac
physiology and pathologies. TRPV1 receptors expressed both on these sensory nerves and on other
non-neuronal cells, as well as the mediators (mainly sensory neuropeptides) released upon their
activation, play important regulatory roles in the development and/or progression of cardiovascular
diseases [11]. However, despite intensive investigation in this field, data are still not coherent regarding
the modulatory effects of TRPV1 and capsaicin-sensitive sensory nerves on cardiac pathologies.
Therefore, in this review, we summarized data on the role of capsaicin-sensitive nerves and TRPV1
channels in cardiac physiology and pathologies and summarized their diagnostic or therapeutic
potential. Available data in the literature so far are mainly obtained from preclinical experiments, since
only a very limited number of clinical investigations have been performed in this field.
2. Capsaicin-Sensitive Sensory Nerves and TRPV1 Receptors in the Heart
TRPV1 is a homotetrameric non-selective cation channel with higher selectivity for Ca2+ over
Na+ [12] composed of transmembrane and cytoplasmic regions. The four identical subunits assemble
around a central aqueous pore, which is located between the 5th and 6th helical segments of the
transmembrane region [13,14], a stretch linking the 5th and 6th segments contains an amphipathic
fragment named the P-loop, which contributes to its permeation properties [15]. TRPV1 receptors are
predominantly localized on the capsaicin-sensitive peptidergic primary sensory neurons innervating the
heart, but also in ventricular cardiomyocytes, vascular smooth muscle, endothelial cells, and epicardial
cells [16]. TRPV1 channels are located in intracellular and mitochondrial membranes as well [17,18].
TRPV1 is activated and/or sensitized by several stimuli produced upon hypoxia, tissue injury and
inflammation including noxious heat (> 43 ◦C) and chemical stimuli like H+ or K+, bradykinin, reactive
oxygen species (ROS), and prostaglandins [19,20]. Activation of TRPV1 induces Na+ and Ca2+ influx
as well as consequent membrane depolarization and the local release of several neuropeptides such as
calcitonin gene-related peptide (CGRP), substance P (SP), and pituitary adenylate cyclase-activating
polypeptide (PACAP) (Figure 1). These peptides contribute to vasodilation, acute phase protein
activation, edema formation, and immune and inflammatory cell activation, collectively called
neurogenic inflammation [21,22]. The pro-inflammatory peptides, inhibitory mediators such as
somatostatin (SST), galanin, and opioid peptides, are also released from the same afferents that induce
anti-edema, anti-inflammatory, analgesic, and cytoprotective actions via entry into the circulatory
system, even at distant parts of the body [21–27]. The role of neurogenic inflammation evoked by the
activation of TRPV1 channels located on the sensory nerve terminals is well-established in several
vascular and dermatological pathologies (e.g., migraine, psoriasis, eczema, etc.) [28–31], but it is much
less characterized in cardiovascular diseases.
The transient receptor potential ankyrin 1 (TRPA1) is a very similar ion channel that is strongly
co-localized with TRPV1 on sensory nerves, vascular smooth muscle cells, and murine cardiomyocytes
at the Z-discs, costameres, and intercalated discs [32]. TRPA1 is also activated by ROS, methylglyoxal,
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hydrogen peroxide, Ca2+, and prostaglandins [33,34], suggesting an interaction between TRPA1
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Figure 1. Localization of the transient receptor potential vanilloid type 1 (TRPV1) channel in different 
cells of the cardiovascular system. Panel (A): Cell bodies of primary sensory neurons innervating the 
heart are localized in the dorsal root ganglia (DRG) and transmit sensory signals to the nucleus tractus 
solitarius (NTS), as well as act as sensory efferents in the heart and the vasculature. Sensory nerves 
are coupled anatomically to sympathetic nerves which are derived from the brain stem reticular 
formation (BSRF), as well as to the vagus nerve (green), which projects afferents to the nucleus 
ambiguus (NA) and possesses motor efferents from dorsal motor nucleus (DMN). SG, sympathetic 
ganglion; NG, nodose ganglion. Panel (B): Several receptors co-localized with TRPV1 on the 
capsaicin-sensitive sensory nerve endings, which mediate a myriad of inflammatory signals including 
cytokines like tumor necrosis factor alpha (TNF-α) and interleukins (e.g., IL-1β), bradykinin (BrK), 
histamine (His), nerve growth factor (NGF; acting on Tropomyosin receptor kinase A—TrkA 
receptors), prostaglandins (e.g., PGE2, PGI2), serotonin (5-HT), and purine mediators (acting at P2 × 
3 purinergic receptors). Noxious stimuli such as ischemia/hypoxia, increased level of reactive oxygen 
species (ROS), noxious heat (> 43 °C), increased levels of K+ or H+ activate TRPV1, and H+ also 
stimulate acid-sensitive ion channels (ASIC). Further ion channels, such as voltage-gated Na+ and Ca2+ 
channels (VGSC, VGCC) may also increase intracellular Na+ and Ca2+ levels, thereby inducing the 
release of peptide mediators, including calcitonin gene related peptide (CGRP), substance P (SP), 
somatostatin (SST), and pituitary adenylate cyclase-activating polypeptide (PACAP). Panel (C) 
demonstrates the localization of TRPV1 channels on different cell types of the heart (CECs, cardiac 
endothelial cells; VSMCs, vascular smooth muscle cells). 
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3. Experimental Tools to Investigate the Function of Capsaicin-Sensitive Sensory Nerves and 
TRPV1 Receptors 
In experimental models, it is important to distinguish the roles of neuronal and non-neuronal 
TRPV1 receptors. TRPV1-expressing capsaicin-sensitive primary sensory neurons are selectively 
Figure 1. Localization of the transient receptor potential vanil oid type 1 (TRPV1) channel in different
cells of the cardiovascular system. Panel (A): Cell bodies of primary sensory neurons in ervating the
heart are localized in the dorsal ro t ganglia (DRG) and transmit sensory signals to the nucleus tractus
solitarius (NTS), as well as act as sensory eff rents in the eart nd the vasculat re. Sensory nerves ar
coupled anatomically to sympathetic nerves which are derived from the b ain stem ret cular formation
(BSRF), as well as to the vagu nerve (green), which proj cts afferents t the nucleus ambiguus (NA)
and posse ses motor effer nts from dorsal moto nucleus (DMN). SG, sympathetic ganglion; NG,
nodose ganglion. Panel (B): Several receptors co-localiz d with TRPV1 on the capsaicin-sensitive
sensory erve endings, which mediate a myriad of inflam atory sig als including cytoki es like
tum r ecrosis factor alpha (TNF-α) and interleukins (e.g., IL-1β), bradykinin (BrK), histamine (His),
nerve growth factor (NGF; acting on Tropomyosin receptor kinase A—TrkA receptors), prostaglandins
(e.g., PGE2, PGI2), serotonin (5-HT), and purine mediators (acting at P2 × 3 purinergic receptors).
Noxious stimuli such as ischemia/hypoxia, increased level of reactive oxygen species (ROS), noxious
heat (> 43 ◦C), increased levels of K+ or H+ activate TRPV1, and H+ also stimulate acid-sensitive ion
channels (ASIC). Further ion channels, such as voltage-gated Na+ and Ca2+ channels (VGSC, VGCC)
may also increase intracellular Na+ and Ca2+ levels, thereby inducing the release of peptide mediators,
including calcitonin gene related peptide (CGRP), substance P (SP), somatostatin (SST), and pituitary
adenylate cyclase-activating polypeptide (PACAP). Panel (C) demonstrates the localization of TRPV1
channels on different cell types of the heart (CECs, cardiac endothelial cells; VSMCs, vascular smooth
muscle cells).
3. Experimental Tools to Investigate the Function of Capsaicin-Sensitive Sensory Nerves and
TRPV1 Receptors
In experimental models, it is important to distinguish the roles of neuronal and non-neuronal
TRPV1 receptors. TRPV1-expressing capsaicin-sensitive primary sensory neurons are selectively
defunctionalized by systemic or perineural high dose capsaicin [35,36] or RTX pre-treatment [37].
After this “chemical denervation”, peptidergic afferents cannot be activated by noxious thermal
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or chemical stimuli and their sensory neuropeptides are depleted [38,39]. Similarly, systemic
administration of high doses of capsaicin (> 50 mg/kg) results in depletion of sensory neuropeptides
from cardiac afferent nerves and the loss of sensory nerve-mediated effects [8,40–42].
Few studies have addressed the expression of the non-neuronal TRPV1 channel in the heart.
DNA microarray and Western blot analyses have revealed the expression of TRPV1 in samples prepared
from whole hearts [43] or, importantly, left ventricular cardiomyocytes [44]. There is experimental
evidence that the expression of non-neuronal TRPV1 receptors, e.g., in keratinocytes, is not affected by
surgical sensory denervation or pretreatment with RTX [45]. Functional studies [46–48] suggest that
activation of non-neuronal TRPV1 receptors expressed on vascular smooth muscle cells (VSMCs) cannot
be inhibited by surgical denervation or pretreatment with high-dose capsaicin abolishing vasodilator
responses evoked by activation of sensory TRPV1 receptors [21–23,47,49–53]. Gene silencing or
genetic knockout of TRPV1 receptors (TRPV1−/−) reduces or completely abrogates the expression
of TRPV1 in both neuronal and non-neuronal structures, but the TRPV1-expressing sensory nerves
can be activated through several other targets. Although global silencing or knockout of TRPV1
is an appropriate experimental tool to investigate the role of this specific ion channel in different
pathologies, a range of adaptative compensatory mechanisms can occur during ontogenesis, and
other receptors can be overexpressed to substitute its function, which is a general limitation of these
models. Moreover, since TRPV1 is expressed in several cell types in the heart such as cardiomyocytes,
vascular smooth muscle, and endothelial cells (see above), its absence in a global TRPV1−/− animal
further complicates the understanding of its exact role in cardiac pathologies. TRPV1 activity can
be modulated by pharmacological agents, such as agonists (e.g., capsaicin or RTX; anandamide,
etc.) and antagonists (e.g., capsazepine, SB705498, iodoresiniferatoxin, etc.), but the lack of their
selectivity and often unfavorable pharmacokinetics provide several limitations. Capsazepine, the
most frequently used TRPV1 antagonist, also blocks voltage-gated K+ and Ca2+ channels [54,55].
Dietary capsaicin administered in several preclinical models [56–58] acts on the sensory nerve terminals
of the gastrointestinal system since it has low oral bioavailability and short plasma elimination
half-life [59]. Although there are reports on the gastrointestinal absorption of capsaicin [60], it does
not get into the systemic circulation in a sufficient amount to act directly on the TRPV1 receptors
of the cardiovascular system [61]. Capsaicin is much more likely to exert anti-atherosclerotic and
cardioprotective effects indirectly by reflex and/or neurohumoral mechanisms via the release of
protective mediators (e.g., sensory neuropeptides such as somatostatin, CGRP, or PACAP) into the
bloodstream that reach the vessels and the heart.
All these factors should be taken into consideration when evaluating the results obtained by these
experimental tools and concluding on the role of TRPV1 receptors in heart diseases.
4. The Capsaicin-Sensitive Sensory Nerves and the TRPV1 Receptor in Cardiac Pathologies
4.1. Coronary Heart Disease
Atherosclerosis is now considered to be a chronic inflammatory disease, which is the primary cause
of coronary artery disease (CAD). Atherosclerotic plaque rupture or erosion causes arterial thrombosis
and results in acute coronary events. Treatment and regression of atherosclerosis to improve CAD
is based on conventional therapy including statins, bile acid sequestrants and proprotein convertase
subtilisin/kexin type 9 (PCSK9) inhibitors (to reduce circulating LDL cholesterol), beta blockers, Ca2+
channel blockers or diuretics (to attenuate intravascular sheer stress and intracellular Ca2+ burden),
and platelet aggregation inhibitors (to prevent intracoronary thrombotic events) [62]. In atherosclerosis
development, inflammasome signaling, including interleukin 1β and 18 signaling pathways, leads to
inflammation, plaque formation, and eventually arterial occlusion [63]. Anti-inflammatory therapy
against atherosclerosis is emerging, and TRPV1 receptors have been shown to participate in different
immune responses [64]. In this section, we will focus on the effects of capsaicin and TRPV1 receptors
on atherosclerosis and CAD, as seen in Table 1.
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4.1.1. In Vitro Studies
In endothelial cells (ECs), activation of TRPV1 leads to the stimulation of endothelial nitric
oxide synthase (eNOS) [52,65]. Nitric oxide is responsible for smooth muscle relaxation leading to
vasodilation, and it simultaneously protects endothelial cells against leukocyte adhesion. Human
umbilical vein endothelial cells (HUVECs) and renal microvascular endothelial cells isolated from
deoxycorticosterone-salt hypertensive mice were cultured and treated with 3–10 µM capsaicin.
The results indicate that the endothelial inflammatory response is attenuated via TRPV1-mediated
Ca2+/PI3K/Akt/eNOS/NO signaling [65]. Capsaicin (from 10 to 50 µmol) repressed ROS generation
and caspase-3 activation in HUVEC cells pretreated with oxidized low-density lipoprotein (oxLDL),
protected macrophage RAW 264.7 cells against foam cell formation, and induced autophagy through
AMP-activated protein kinase signaling pathway in oxLDL-treated vascular smooth muscle cells
(VSMCs), which suggests a protective role of TRPV1 activation against oxLDL-induced vascular
dysfunctions [66,67]. TRPV1 activation by capsaicin concentration dependently increased cytosolic
Ca2+, and significantly reduced the accumulation of lipids and cholesterol uptake in VSMCs of wild
type, but not ApoE−/−/TRPV1−/−, animals. The mechanism of action for these beneficial effects of
TRPV1 activation was Ca2+-, calcineurin- and protein kinase A-dependent via increased expression
of ATP-binding cassette transporter A1 (ABCA1) and reduced expression of LDL-related protein 1
(LRP1) [57]. Lipopolysaccharide (LPS)-induced upregulation of proinflammatory cytokines including
TNF-α, IL-1β, and IL-6 were markedly suppressed by the capsaicin analog dihydrocapsaicin in human
monocytic THP-1 macrophage cell cultures through enhancing nuclear factor IA and inhibiting NF-κB
expression [58].
4.1.2. In Vivo Studies
Most in vivo studies targeting TRPV1 in animal models of atherosclerosis use dietary capsaicin
treatment to achieve improvement either in atherosclerotic plaque reduction or in the accompanying
inflammation. As we indicated in the above section, oral capsaicin treatment cannot directly act
on cardiac or intravascular TRPV1 receptors, therefore, a remote activation should be suggested,
which likely involves TRPV1 receptors localized on the capsaicin-sensitive sensory nerve terminals [68]
and/or the intestinal epithelial cells [69]. The ApoE−/− mouse is the most frequently used model to
study atherosclerosis [70].
Dietary Models
Four weeks of oral treatment with evodiamine (TRPV1 agonist) induced atheroprotection in
ApoE−/− mice, but not in ApoE−/−/TRPV1−/− mice, by alleviating hyperlipidemia and systemic
inflammation as well as hepatic macrovesicular steatosis. However, the anti-obesity effect of evodiamine
was preserved after genetic ablation of TRPV1, suggesting a TRPV1-independent mechanism [71].
Daily oral dihydrocapsaicin treatment for 12 weeks decreased proinflammatory cytokine (TNF-α,
IL-1β, and IL-6) levels in the serum and in the aortic plaque of ApoE−/− mice [58].
Low doses of oral capsaicin for 24 weeks reduced lipid storage and atherosclerotic lesions in the
aorta isolated from ApoE−/− mice, but not from ApoE−/−TRPV1−/− mice, on a high-fat diet [57].
In a recent study, ApoE−/−/TRPV1−/− mice were fed with either standard chow or a high-fat
diet (HFD) supplemented with 0.01% capsaicin for 24 weeks. TRPV1 deficiency combined with the
HFD led to coronary dysfunction, increased ROS generation, and reduced endothelial NO production.
Dietary capsaicin supplementation enhanced coronary relaxation and prolonged the survival of
HFD-fed ApoE−/− mice, but not in ApoE−/−/TRPV1−/− mice. Capsaicin upregulates uncoupling protein
2 expression via protein kinase A phosphorylation, thereby alleviating endothelial mitochondrial
dysfunction and inhibiting mitochondrial ROS generation [56]. Guinea pigs fed by HFD for 14 weeks
developed severe dyslipidemia associated with histological changes and endothelial dysfunction.
Oral administration of capsaicin (2.5 mg/kg, 5 mg/kg, or 10 mg/kg once a day for 14 weeks) decreased
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serum levels of total cholesterol, triglycerides, LDL cholesterol, and apo B-100, and increased HDL
cholesterol, as well as alleviated the plaque area, plaque area to intima ratio, and intima thickness,
and also decreased the oxidative stress marker malondialdehyde and endothelin-1 levels. Therefore,
dietary capsaicin supplementation may represent a promising solution for the primary prevention of
CAD. However, the mechanisms between the activation of most likely the intestinal TRPV1 receptors
and the vasculature to reduce atherosclerotic plaques are currently unknown.
Non-Pharmacological TRPV1 Activation
Activation of TRPV1 channels by capsaicin may reduce lipid storage and the formation of
atherosclerotic lesions as described above. However, clinical use of capsaicin has been limited by its
chronic toxicity, since long-term capsaicin consumption could damage TRPV1-expressing sensory
nerves or neurons [50]. Recently, Gao et al. showed that coupling of copper sulfide (CuS) nanoparticles
to antibodies targeting TRPV1 acts as a photothermal switch for TRPV1 signaling in VSMCs using
near-infrared light. ApoE−/− mice were fed with high-fat chow and near-infrared light was applied
locally to increase the local temperature, which opened thermo-sensitive TRPV1 channels and caused
Ca2+ influx. The influx of Ca2+ activated the autophagy–lysosome pathway and impeded foam cell
formation in VSMCs treated with ox-LDL [72]. This alternative non-pharmacological way of TRPV1
activation may represent a novel therapeutic tool to improve atherosclerosis.
Table 1. Summary of the roles of TRPV1 channels in atherosclerosis.
TRPV1 Activation Experimental Model Beneficial Effects of TRPV1 Activation Reference(s)
capsaicin
in vitro
HUVEC cell culture reduced oxLDL induced ROS generation [66]
in vivo by dietary capsaicin VSMC of WT or TRPV1 KOmice on high-fat diet reduced foam cell formation [67]
dihydrocapsaicin human monocytic THP-1macrophage cell culture
downregulated LPS induced proinflammatory
cytokines (TNF-α, IL-1β and IL-6) [58]
capsaicin VSMC of ApoE, TRPV1double KO mouse reduced lipid accumulation [57]
CuS-TRPV1 antibody
nanoparticles excited by near
infrared light
VSMC of ApoE KO mouse inhibited foam cell formation [72]
dietary capsaicin (24 weeks)
in vivo
Apo E, TRPV1 double KO
mouse on high-fat diet
reduced lipid storage and atherosclerotic
lesions [57]
daily oral gavage of
dihydrocapsaicin (12 weeks)
Apo E KO mouse on high
fat diet
downregulated proinflammatory cytokines
(TNF-α, IL-1β and IL-6) [58]
dietary evodiamine activation Apo E, TRPV1 doubleKO mouse
alleviation of hyperlipidemia, inflammation
and hepatic macrovesicular steatosis [71]
dietary capsaicin (24 weeks) ApoE, TRPV1 double KOmouse on high-fat diet
prolonged survival, upregulated uncoupling
protein 2 expression [56]
CuS-TRPV1 antibody
nanoparticles excited by near
infrared light
ApoE KO mouse attenuated atherosclerotic lesion [72]
4.1.3. Summary
TRPV1 modulates the physiological and pathophysiological functions of vascular endothelial
cells; its role in atherosclerosis is clearly demonstrated in preclinical studies. The activation of this
receptor/ion channel seems to be beneficial. TRPV1 modulates the inflammatory response of endothelial
cells, therefore, activation of TRPV1 should be considered as a new potential therapeutic target for
the treatment of inflammatory vascular diseases, especially for atherosclerosis. However, further
transcriptomics and proteomics studies would be essential to elucidate all players of the beneficial
effects of TRPV1 and/or capsaicin-sensitive sensory nerve activation in atherosclerosis and CAD.
4.2. Myocardial Infarction and Cardioprotection
Acute myocardial infarction (AMI) is the most severe consequence of coronary atherosclerosis.
The introduction of primary coronary angioplasty in the late 1970s dramatically decreased the mortality
of AMI patients. However, late complications, such as postischemic heart failure, have been rising.
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Revelation of the nature of ischemia/reperfusion (I/R) injury led to the discovery of cardiac ischemic
adaptation, such as local and remote ischemic pre- and postconditioning; however, their efficacy is
affected by several comorbidities including sensory neuropathy [73,74]. Cardiac TRPV1-expressing
sensory nerves and their peptide mediators (e.g., CGRP and SP) released after activation have been
implicated in both local and remote cardioprotective mechanisms, but their exact roles are still
debated. In the following section, we discuss the beneficial and detrimental contribution of TRPV1 and
capsaicin-sensitive afferents, as well as their neuropeptides, to cardioprotection against myocardial I/R
injury (see summary in Table 2).
4.2.1. Acute Infarction
Sensory Nerve Desensitization
In an early study, a decreased cardiac level of SP was shown in myocardial ischemia; however,
administration of SP attenuated ischemic myocardial damage in Langendorff-perfused hearts of
rats subjected to systemic capsaicin pretreatment [75]. Two days after systemic high-dose capsaicin
pretreatment, farm pigs subjected to coronary artery occlusion developed significantly higher infarct
sizes, which were accompanied with decreased myocardial CGRP levels as compared to the control
animals [42]. The same aggravation of myocardial damage was observed in rats 12 weeks after
systemic capsaicin pretreatment at neonatal age, when infarct size was measured 6 h after coronary
occlusion [76]. Interestingly, there are 2 case reports published on young male patients taking cayenne
pepper pills for 5 days [77] and 3 months [78], respectively, who developed AMI without the presence
of any risk factors or anamnestic data for physical or emotional stress. All the above studies and
reports suggest that capsaicin-sensitive sensory nerves have a cardioprotective role against myocardial
ischemic injury, at least partially due to the release of their neuropeptides including CGRP and SP.
TRPV1 Modulation
Capsaicin-induced TRPV1 activation in H9C2 cardiomyocytes enhanced apoptosis by increasing
intracellular Ca2+ and mitochondrial superoxide levels, while treatment with capsazepine or TRPV1
siRNA significantly improved cell viability after hypoxia/reoxygenation (H/R) injury [79]. In contrast,
TRPV1 activation has a significant cardioprotective role following myocardial I/R injury. Jiang et al.
investigated the effects of TRPV1 activation on myocardial apoptosis in response to ex vivo I/R in
TRPV1−/− and wild type mice. To assess information about downstream signaling mechanism of
TRPV1 activation by measuring phosphorylated and unphosphorylated extracellular signal-regulated
protein kinase 1/2 (ERK1/2) and B-cell lymphoma 2 (Bcl-2)/Bcl-2 associated X protein (Bax) levels,
they also tested I/R injury in the presence or absence of the phosphatidylinositol 3-kinase inhibitor
(PI3KI), LY294002. Myocardial apoptosis and infarct size were significantly greater in TRPV1−/−
hearts following I/R compared with wild types and sham controls. Prior to I/R, treatment with PI3KI
significantly increased myocardial apoptosis and infarct size in the wild type group, but neither have
changed in TRPV1−/− mice, which suggests that TRPV1 serves a protective role via the PI3K/Akt
signaling pathway [80]. Moreover, Wang et al. performed a comparative study on pharmacological
and genetic depletion of TRPV1 in postischemic recovery of isolated mouse hearts. Interestingly,
acute pharmacological blockade of TRPV1 with capsazepine in WT mouse hearts led to more severe
impairment of postischemic recovery than that observed in the TRPV1−/− hearts. These results
suggest that the long-term absence of TRPV1 induces compensatory mechanisms to substitute TRPV1
functions [81].
Similarly, CGRP-induced cardioprotection against AMI was demonstrated in both rodent and
large animal models [42,82].
Nerve growth factor (NGF) has a key role in upregulating TRPV1 expression in peptidergic
sensory neurons of adult rats [83] via the NGF-TrkA signaling. Knocking down spinal NGF had
myocardial protective effect against ischemic injury similarly to the effect of capsazepine in a rat AMI
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model [84,85]. However, it is important to note that the sample size used in these studies were low,
n = 3 and n = 6, respectively.
In contrast, the cardioprotective role of TRPV1 receptors after adenoviral delivery of the NGF
gene was supported in normal and combined streptozotocin- and high fat diet-induced diabetic mouse
hearts subjected to I/R injury ex vivo. Elevated levels of CGRP, but not SP, were found, which was
accompanied by improved cardiac functions in both groups [86]. A recent study showed that in the
heart of normal rats treated with the antidiabetic drug dipeptidyl peptidase 4 inhibitor sitagliptin
orally for 2 weeks, TRPV1 and also CGRP protein levels were increased. Moreover, capsazepine
co-administered with sitagliptin orally for 2 weeks abolished the cardioprotective effect of DPP-4
inhibition when rat hearts were subjected to I/R injury [87].
Morphine, a major analgesic drug used to alleviate severe pain accompanied with AMI, was shown
to protect the heart against I/R injury, and this protection was partially mediated by TRPV1 receptors
since TRPV1 receptor antagonists (capsazepine or P5, a peptide analgesic and TRPV1 inhibitor), prior to
coronary occlusion, abrogated the cardioprotective effects of morphine [88].
4.2.2. Ischemic Conditioning
The endogenous ischemic adaptation phenomena, including different forms of ischemic pre-
and postconditioning, may involve capsaicin-sensitive nerve- or TRPV1-mediated cardioprotection.
In ischemic preconditioning (IPC), the critical role of TRPV1 receptors was demonstrated by TRPV1
gene deletion, which abolished SP- and CGRP-mediated cardioprotection evoked by IPC [89].
Sensory Nerve Desensitization
Our research group has shown for the first time in the literature that capsaicin-sensitive sensory
nerves are involved in preconditioning-induced cardioprotection evoked by rapid ventricular pacing.
Preconditioning stimuli facilitated the release of CGRP and nitric oxide from capsaicin-sensitive
nerves [40,90], which was abolished by systemic capsaicin treatment-induced sensory desensitization.
Later on, a research group from the Hunan Medical University, China, demonstrated that systemic
high dose (50 mg/kg) capsaicin treatment abrogates the cardioprotective effects of ischemia-,
CGRP-, bradykinin-, and monophosphoryl lipid A-induced early or delayed preconditioning,
respectively [91–94]. They have shown a significant decrease in the number of CGRP positive neurons,
as well as decreased plasma CGRP levels, in the capsaicin-treated groups in each experimental setup.
TRPV1 Modulation
Remote IPC triggered by short episodes of hindlimb ischemia in rats was shown to be transferred
at least partially by TRPV1 channels, since elevated left ventricular TRPV1 expression was measured
after remote IPC as compared to control ischemic animals [95]. TRPV1 activation-induced CGRP release
have been shown to participate in sensory nerve-mediated cardioprotection. The cardioprotective effect
of limb ischemia-induced remote ischemic postconditioning was shown to be abrogated by capsazepine,
the CGRP antagonist CGRP8–37, and the SP antagonist RP67580, respectively, as administered IV
separately to rats [96]. Moreover, decreased myocardial TRPV1 expression was accompanied by reduced
CGRP and SP release into coronary effluent after myocardial ischemia in the isolated hearts of type I
diabetic rats as compared to non-diabetic ones, leading to the loss of ischemic postconditioning-induced
cardioprotection and impaired myocardial function [97].
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Table 2. Role of the capsaicin-sensitive peptidergic nerves and the TRPV1 channel in I/R injury, AMI,
and cardiac ischemic conditions.
Experimental Model TRPV1Modulation
Effects of TRPV1 on Major
Study Endpoints
Role of TRPV1
Activation Reference
AMI + sensory
desensitization
farm pig
high dose capsaicin ↓
decreased infarct size and
increased CGRP level beneficial [42]
in vivo rat
neonatal capsaicin treatment ↓ decreased infarct beneficial [77]
Ischemia reperfusion
injury
H9C2 cell,
capsazepine or TRPV1 siRNA ↓ decreased cell viability detrimental [79]
ex vivo
TRPV1 KO mouse ↓ decreased infarct size beneficial [80]
ex vivo
TRPV1 KO mouse,
capsazepine
↓ improved systolic and diastolicfunctions beneficial [81]
in vivo rat
Lentivirus-mediated spinal NGF
gene knockdown-induced TRPV1
downregulation
↓ increased infarct size detrimental [84]
in vivo rat
Lentivirus-mediated spinal NGF
gene knockdown-induced TRPV1
downregulation or capsazepine
induced TRPV1 inhibition
↓ increased infarct size detrimental [85]
ex vivo diabetic mouse
Adenovirus-mediated NGF gene
delivery induced TRPV1
upregulation
↑
Elevated cardiac CGRP level and
improved systolic and diastolic
functions
beneficial [86]
Sitagliptin-induced
cardioprotection
ex vivo rat AMI,
capsazepine and
co-administration of sitagliptin
↓ capsazepine abolished infarct sizelimiting effects of sitagliptin beneficial [87]
Morphine-induced
cardioprotection
in vivo rat AMI,
capsazepine or P5 ↓ decreased infarct size beneficial [88]
Early or delayed
preconditioning
in vivo/ex vivo rat AMI
high dose capsaicin ↓
abolished
preconditioning-induced
cardioprotection
beneficial [91–94]
Pacing-induced
preconditioning ex vivo rat AMI ↓
abolished
preconditioning-induced
cardioprotection
beneficial [40]
Remote ischemic
preconditioning
in vivo rat AMI,
RIPC induced TRPV1
upregulation
↑ decreased infarct size beneficial [95]
Remote ischemic
postconditioning
in vivo rat AMI,
capsazepine ↓ decreased infarct size beneficial [96]
Ischemic
postconditioning
type 1 diabetic rat ex vivo AMI,
capsazepine ↓
abolished IPost-induced
cardioprotection beneficial [97]
4.2.3. Summary
These experimental data show predominantly protective roles of cardiac capsaicin-sensitive
afferents and sensory TRPV1 receptors in myocardial protection through the release of sensory
neuropeptides. However, involvement of TRPV1 receptors expressed by cardiomyocytes [43,98]
and endothelial cells has not been investigated. Although several studies have been performed to
investigate the alterations in proteomics or transcriptomics, including microRNA (miRNA)-omics,
related to myocardial I/R injury or cardioprotective maneuvers like ischemic conditionings, surprisingly,
involvement of TRPV1 or capsaicin-sensitive sensory nerves in such studies is still an unmet need.
4.3. Heart Failure
Heart failure (HF) is a complex clinical syndrome resulting from the decreased function of the
right, left, or both ventricles. The symptoms derive from an inadequate cardiac output, since the
failing heart is unable to keep up with the demands [99]. Three main phenotypes describe HF based
on the measurement of the left ventricular ejection fraction (EF). HF with reduced ejection fraction
(HFrEF), HF with preserved EF (HFpEF), and HF with mid-range EF (HFmrEF) [100]. As we indicated
in the previous section, increased survival rate after AMI due to recanalization of the coronaries via
percutaneous coronary intervention constitutes one of the major sources for HFrEF patients. However,
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since causal therapy is not available against HFrEF, there is an utmost need to discover novel pathways
and targets to improve cardiac function and prolong life expectancy of HF patients.
The roles of capsaicin-sensitive sensory nerves and/or TRPV1 receptors in the development or
progression of HF have been investigated intensively in the last 2 decades. Various animal models
of HF including post-infarction-, high salt diet/hypertension-, pressure overload-, or toxic cardiac
injury (e.g., doxorubicin)-induced models showed important roles of TRPV1 in HF. However, its exact
function in the pathophysiological mechanisms, as well as its appraisal, still remains unclear (see
Table 3 for details).
4.3.1. Sensory Desensitization in HF Studies
In rats, neonatal capsaicin treatment ablating the capsaicin-sensitive fibers resulted in an enhanced
pressor response to exercise comparable to post-infarction HF, and altered the activity and sensitivity of
the sensory fibers in HF [101]. Our research group has previously shown that capsaicin-induced sensory
desensitization causes an impaired myocardial relaxation characterized by increased LV end-diastolic
pressure [102]. We have also demonstrated that systemic capsaicin treatment can aggravate myocardial
dysfunction induced by adriamycin-evoked congestive cardiomyopathy [8]. However, cardiac effects
of systemic sensory desensitization have not yet been investigated in the presence of other etiologies
of HF. Recently, we have found an increased end-diastolic diameter, and reduced stroke volume,
but maintained EF and FS, after systemic capsaicin-induced sensory desensitization in rats [103].
Disturbed relaxation was due to reduced basal cardiac NO, superoxide, and peroxynitrite (ONOO−)
formation, and thereby impairment of the physiological S-nitrosylation level of the sarco-endoplasmic
reticulum Ca2+ ATPase 2a (SERCA2a) [104]. Moreover, we have also investigated the effects of
systemic capsaicin-induced sensory neuropathy on cardiac miRNA transcriptomics and shown an
altered miRNA expression pattern. We further characterized the altered cardiac miRNA profile by
using unbiased bioinformatic target prediction and identified as well as evaluated novel target genes,
which can be responsible for the development of diastolic dysfunction (for details, see reference [103]).
This model of sensory neuropathy due to capsaicin-induced sensory desensitization provides an
experimental HFpEF model. The role of TRPV1 in the development of HFpEF has not been investigated
so far. In contrast with these results, high dose RTX treatment resulting in complete epicardial ablation
of TRPV1-expressing nerves on the surface of the rat heart led to a significantly improved HF indicated
by LV systolic and diastolic diameters and volumes, but infarct size was not affected [105]. In addition
to the latter study, intrathecal RTX treatment in rats ablating the TRPV1+ afferents in the spinal cord
protected the heart against TAC-induced interstitial fibrosis and attenuated LV hypertrophy. Eight
weeks after the surgery, the rats had similar systolic parameters, including EF and FS, to sham rats [106].
4.3.2. Studies on Pharmacological and Genetic Ablation of TRPV1
Post-Infarction HF
Two research groups [101,107] investigated the relationships between exercise pressor reflex
(EPR) and TRPV1 in HF. Both studies showed that mRNA expression of TRPV1 was significantly
downregulated in rats with coronary ligation-induced dilative cardiomyopathy [101,107]. Wang et al.
showed that group III afferents (predominantly mechanically sensitive) are sensitized and group IV
afferents (predominantly metabolically sensitive) are blunted in rats with post-infarction HF [107].
In TRPV1−/−mice, TGF-β and Smad2 expression were upregulated, and the infarct size was significantly
greater 7 days after permanent ligation of the left coronary artery as compared to wild types [108].
Moreover, in the hearts of end-stage HF patients, TRPV1 mRNA expression showed an increasing
tendency as compared to healthy controls [109].
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Chronic Hypertension-Induced HF
An early study using Dahl salt-sensitive and salt-resistant rats subjected to low- and high-salt diets
for 3 weeks was the first to show that TRPV1 protein expressions in mesenteric arteries and kidney
samples are upregulated due to increased salt intake and the overexpression of TRPV1 prevents the
development of salt-induced hypertension only in salt-resistant animals [110]. Lang et al. [111]
investigated the effect of daily capsaicin intake for 24 weeks in high-salt diet-induced cardiac
hypertrophy in TRPV1−/− mice. They showed that after chronic dietary capsaicin intake, mitochondrial
Complex I activity, ATP production, and citrate synthase activity were significantly increased,
and mitochondrial sirtuin 3 was upregulated in WT mice on high-salt diet through a TRPV1-dependent
manner since these alterations were not manifested in TRPV1−/− mice [111].
Pressure Overload-Induced HF
In rodent models of transverse aortic constriction (TAC), which is employed to induce cardiac
pressure overload, thereby cardiac hypertrophy and HF, the role of TRPV1 has intensively been
investigated in the last decade. It has been disclosed that TAC-induced pressure overload upregulates
cardiac TRPV1 expression [112]. Mice lacking functional TRPV1 developed significantly reduced
cardiac hypertrophy induced by TAC measured over time until 8 weeks after TAC [113]. However,
4 weeks after TAC-induced ventricular hypertrophy, TRPV1−/− mice had significantly decreased LV
ejection fraction (EF) and fractional shortening (FS) as well as significantly increased secretion of
pro-inflammatory cytokines, TNFα and IL-6 [112]. In a suprarenal aortic banding-induced HF model,
10 weeks of 0.01% dietary capsaicin intake significantly attenuated the hypertrophic response in WT
mice, but not in TRPV1−/− mice [114].
HF Models of Toxic Cardiac Injury
Indirect evidence supports the protective role of TRPV1 channels against anthracycline
(i.e., doxorubicin)-induced HF in rat model [115–117]. Eugenol, as an active component of clove oil, is
an antioxidant as well as a TRPV1 activator and has previously been shown to possess cardioprotective
effects [118]. Eugenol administered orally for five days for doxorubicin-treated rats improved cardiac
function, which was abolished by capsazepine [117]. A recent study was consistent with the above
findings, where the authors treated wild-type mice and mitochondrial aldehyde dehydrogenase
2-overexpressing transgenic (ALDH2TG) mice with doxorubicin to induce congestive heart failure
characterized by left ventricular dysfunction and chamber dilation [116]. ALDH2 was previously
found to be cardioprotective against ischemia-reperfusion injury and alcoholic cardiomyopathy due
to detoxification of toxic reactive aldehydes [119]. SA13353, a TRPV1 agonist, was administered
to wild type mice, and parallelly, capsazepine was administered to ALDH2TG mice to assess the
involvement of TRPV1 receptors in the protection of ALDH2 against doxorubicin-induced cardiac
dysfunction. Treatment of wild type mice with SA13353 led to improved cardiac function, while
capsazepine administered to ALDH2TG mice abrogated increased contractility evoked by ALDH2
overexpression, respectively, which indicates that cardioprotection induced by ALDH2 overexpression
against doxorubicin-induced heart failure is mediated at least partially by TRPV1. The latter finding
was confirmed at the cellular level in cultured cardiac myocytes [116].
It is interesting to note that the role of TRPV1 in cardiac dysfunction associated with sepsis and
endotoxemia is also under investigation. Chen et al. [120] showed the cardioprotective role of TRPV1
in a mouse model of LPS-induced endotoxemia in TRPV1−/− mice. Low-dose LPS did not cause
any cardiac dysfunction in wild type mice, but led to a significant reduction in EF, FS, and fraction
area change% (FAC), and caused bradycardia in TRPV1−/− mice. Results after the TRPV1 antagonist
AMG-9810 treatment were similar to TRPV1 deletion, suggesting that TRPV1 may have a key role in
cardioprotection against endotoxin-induced cardiac dysfunction [120].
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Table 3. Summary for the role of TRPV1 channels in HF.
Treatment to Modulate TRPV1 TRPV1 up- orDownmodulation Experimental Model
Effect of Treatment on Major Study
Endpoints
Role of TRPV1 Activation on
Cardiac Remodeling Reference(s)
Capsaicin-sensitive sensory
nerve desensitization
neonatal capsaicin treatment ↓ neonatal capsaicin treatment, dilatedcardiomyopathy (DCM) and control rat enhanced EPR compared to control detrimental [101]
epicardial TRPV1 ablation by high dose RTX epicardial ↓ post-MI-induced HF with RTX treatmentin rat improved cardiac compliance detrimental [105]
intrathecal RTX treatment spinal cord ↓ transverse aortic constriction(TAC)-induced HF improved cardiac function detrimental [106]
sc. capsaicin treatment for 3 days at
increasing doses ↓ sensory neuropathy-induced HFpEF impaired myocardial relaxation beneficial [103,104]
Pharmacological or genetic
modulation of the
TRPV1 receptor
genetic deletion ↓ 7 days post-MI mouse increased infarct size beneficial [108]
genetic deletion and dietary capsaicin for 24 weeks ↑ high-salt diet-induced cardiachypertrophy, mouse improved mitochondrial function beneficial [111]
TRPV1 gene disruption ↓ TAC-induced HF reduced cardiac hypertrophy detrimental [113]
genetic deletion ↓ TAC-induced HF decreased cardiac function andincreased TNFα and IL-6 beneficial [112]
genetic deletion and dietary capsaicin for 10 weeks ↑ TAC-induced HF attenuated hypertrophy in WT beneficial [114]
TRPV1 activation by eugenol, capsazepine ↑ acute doxorubicin cardiotoxicity improved cardiac function beneficial [117]
SA13353 TRPV1 agonist, and capsazepine ↑ doxorubicin-induced HF, ALDH2transgene mouse improved cardiac function beneficial [116]
genetic deletion, AMG-9810 TRPV1 antagonist ↓ LPS-induced endotoxemia, mouse cardiac dysfunction beneficial [120]
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4.3.3. Summary
The vast majority of the studies demonstrate cardioprotective roles of the capsaicin-sensitive
nerves and TRPV1 receptors on cardiac functions independently of the etiology of HF. Although
some studies reported on beneficial effects after the depletion of TRPV1-expressing nerves/neurons,
these studies used either extracardiac desensitization [106] or superficial treatment (i.e., painting the
epicardium with a brush immersed into RTX solution) [105] to deplete epicardial TRPV1 receptors.
4.4. Arrhythmias and Electrophysiology
Cardiac arrhythmias can be classified as ventricular and supraventricular arrhythmias. Excessive
sympathetic activity contributes to structural and electrical remodeling of the myocardium in different
cardiac pathologies including AMI and HF and increases arrhythmia susceptibility, the incidence
of severe ventricular arrhythmias, and sudden cardiac death [121,122]. Approximately half of all
mortality in chronic HF is due to sudden cardiac death, a significant proportion of which is caused
by ventricular tachyarrhythmias [123]. Reperfusion of previously ischemic myocardium (e.g., during
recanalization following AMI) can also lead to the development of severe ventricular arrhythmias
both in preclinical and clinical settings [124,125]. Only a few studies investigated the effects of TRPV1
modulators on cardiac electrophysiology and arrhythmias in experimental models.
4.4.1. Ventricular Arrhythmias
TRPV1-Independent Cardiac Actions of Capsaicin and RTX
The TRPV1-independent actions of capsaicin and RTX on cardiac K+ channels were demonstrated
in a somewhat contradictory study. Capsaicin prolonged single cell APD and inhibited the transient
outward K+ current (Ito), a voltage dependent non-inactivating outward current (IK), and the inward
rectifier K+ current (IK1) currents in isolated adult rat ventricular cardiac myocytes [126]. Interestingly,
the capsaicin analogue zingerone exhibited similar effects, but RTX did not influence any of these
currents [126]. To resolve this contradiction, the author clarified the differential effects of capsaicin and
RTX on K+ channels by differential structural requirements for K+ channel blockade in the heart as
compared to those required to produce neuroexcitatory effects. This finding also indicates that the
vanillyl moiety of capsaicin and zingerone is essential for blocking cardiac K+ channels. In guinea
pig ventricular papillary muscle preparations, capsaicin significantly shortened the action potential
duration (APD) and did not influence the maximum rate of depolarization, suggesting no voltage-gated
Na+ channel (INa) involvement. The authors speculated that AP shortening and antiarrhythmic effect
of capsaicin was due to the blockade of voltage-gated Ca2+ channels (ICaL), although no ionic currents
were measured [127].
Sensory Desensitization Studies on Ventricular Arrhythmias
In a rat model with HF induced by 4-week coronary ligation, intrathecal RTX pre-treatment
significantly reduced dorsal horn TRPV1 expression and reduced cardiac sympathetic nerve
overactivation, which reversed epicardial monophasic APD prolongation and decreased action
potential alternans and ventricular arrhythmia development evoked by programmed electrical
stimulation [128]. In a porcine model of AMI induced by permanent obliteration of the left
anterior coronary artery, capsaicin-sensitive nerve defunctionalization evoked by epicardial RTX
administration prevented ventricular tachycardia and fibrillation induced by programmed electrical
stimulation [129]. In RTX-treated AMI pigs, no changes were observed in cardiomyocyte action potential
parameters, ion channel expression, or calcium transients at the infarct border zone, while electrical
heterogeneity, fibrosis, and altered distribution of connexin 43 was attenuated compared to untreated
AMI animals [129].
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Studies on Pharmacological and Genetic Ablation of TRPV1
In an early study, the incidence of ventricular tachycardia and fibrillation induced by either
global or regional myocardial ischemia was reduced in isolated guinea pig and rat hearts, respectively,
when 30 µM capsaicin was administered to Krebs-Henseleit solution prior to ischemia [127]. In rats
subjected to 30 min of myocardial ischemia followed by 120 min reperfusion, TRPV1 mRNA was
upregulated in the dorsal root ganglia (DRG) neurons [130]. Arrhythmia score along with infarct size
was significantly reduced when TRPV1 upregulation was suppressed by lentiviral TRPV1 gene silencing
in the DRG. Similar antiarrhythmic effects were observed after exposure to the TRPV1 antagonist
iodoresiniferatoxin [130]. Recent studies suggest that chronically elevated cardiac sympathetic
excitation driven by persistent TRPV1 afferent signaling in pig and rat models, respectively, is
associated with cardiac remodeling and arrhythmia generation [128,129]. Importantly, TRPV1 has also
been identified as the regulated molecular component of the atrial natriuretic signaling pathway and
as a potential molecular target in HF and cardiac hypertrophy induced by TAC in mice. Reduction of
cardiac structural and electrical remodeling in HF by beneficial modulation of the atrial natriuretic
signaling pathway may markedly decrease both arrhythmia substrate and triggered activity [131].
4.4.2. Supraventricular Arrhythmias
Atrial fibrillation (AF) is the most common chronic arrhythmia with multiple underlying
mechanisms, particularly heart failure, where AF prevalence is approximately up to 40% at time of
hospitalization [132]. The autonomic nervous system critically influences atrial electrophysiology,
and its dysfunction is considered to be a major factor in the initiation and maintenance of AF [133].
However, little is known about a possible link between capsaicin-sensitive sensory nerves/TRPV1
function/dysfunction and AF. Obstructive sleep apnea is associated with the development of AF
via its effects mediated by the cardiac autonomic nervous system [134]. In a very recent study, the
injection of RTX into the cardiac ganglionated plexi (GP) decreased nerve and stellate ganglion activity,
abolished sleep apnea, induced the shortening of the effective refractory period (ERP), and completely
inhibited AF induction in a dog model of sleep apnea [135]. In patients with non-valvular AF, a marked
increase in TRPV1 expression was found in leukocytes compared to control patients without AF [136],
suggesting enhanced systemic inflammatory response status and oxidative stress in patients with
non-valvular AF, both identified as important contributors to AF induction and maintenance [137].
4.4.3. Summary
In summary, these relatively few studies investigating the cardiac electrophysiological effects
of TRPV1 and its modulators suggest that TRPV1 plays a significant role in arrhythmogenic cardiac
electrical and structural remodeling associated with AMI, HF, and AF. Importantly, different TRPV1
modulators have been shown to possess different direct cardiac ion channel effects, which need to be
further explored in order to dissect the role of TRPV1 in cardiac electrophysiology and arrhythmias,
preferably in animal models that are relevant to human diseases [138,139].
4.5. Congenital Heart Diseases
Congenital heart diseases (CHD) are among the most common birth defects [140]. Malformations
of the developing heart during the intrauterine life are related to both genetic and environmental factors.
Ebstein’s anomaly, Fallot tetralogy, and Wolff-Parkinson-White syndrome did not show connection with
the TRPV1 receptor. On the other hand, environmental factors, like heat (e.g., maternal fever during the
first trimester) showed correlation to CHD [141]. Based on these phenomena Hutson et al. designed
a proof-of-concept study with chick embryos and reported that heat-activated TRPV1 and TRPV4
channels were present in neural crest cells during critical window of heart development and they
induced fever-associated defects. These data provided a mechanism for hyperthermia-activated TRPV1
ion channel activation resulting in congenital heart defects. Blocking TRPV1 during heat exposure
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mitigated most of the hyperthermia-induced heart malformations [142]. This special field of cardiology
requires more intensive investigations to reveal the role of TRPV channels in heart development.
5. Conclusions and Future Perspectives
This review summarizes the data about the role of the cardiac capsaicin-sensitive sensory
nerves and the TRPV1 receptor in cardiac pathologies, including coronary heart disease, myocardial
infarction, heart failure, and arrhythmias. Sensory neuronal TRPV1 activation seems to play a
crucial role in reducing atherosclerosis and confers significant cardioprotective effects against ischemic
damage. However, although little is known about TRPV1 functions in cardiac electrophysiology,
it is likely to play a role in supraventricular and ventricular arrhythmogenesis. Although most
data suggest that stimulation of the TRPV1-expressing sensory nerves or the TRPV1 channel might
have beneficial effects in cardiac diseases, this conclusion should be cautious. The interactions of
other ion channels and receptors expressed on the capsaicin-sensitive sensory afferents with TRPV1,
as well as the actions of TRPV1 channel activation on non-neuronal cell types in the heart, are
not precisely known. Therefore, future studies should target cell type-specific TRPV1 receptors,
use more selective pharmacological interventions, and analyze clinical samples to elucidate the role
and mechanism of action of sensory and non-neuronal TRPV1 signaling, as well as to determine its
value for potential novel therapies. Multi-omics studies, including transcriptomics, microRNAomics,
and proteomics, as well as bioinformatic synthesis of the data, are required to discover the signaling of
the TRPV1 channel and capsaicin-sensitive sensory nerves in cardiac pathologies in an unbiased manner.
Our previous omics studies [43,103] on cardiac capsaicin-sensitive sensory nerves revealed some novel
potential targets, which should be further validated in vivo. However, we investigated the effects of
sensory desensitization alone on cardiac function and metabolism. In future omics studies, sensory
desensitization or pharmacological/genetic ablation of TRPV1 should be combined with conventional
cardiac pathology models to elucidate further targets, which may contribute to the pathomechanism of
ischemic heart diseases, heart failure, or cardiac arrhythmias due to the lack/dysfunction of sensory
nerves/TRPV1 channels. Moreover, large animal models of sensory desensitization/TRPV1 ablation
combined with cardiac diseases are essential to be developed to gain translatable findings, which can
be used to develop adaptable therapies for humans.
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5-HT Serotonin
ABCA1 ATP-binding cassette transporter A1
ALDH2 Aldehyde dehydrogenase 2
AMI Acute myocardial infarction
APD Action potential duration
ASIC Acid-sensitive ion channels
BAX B-cell lymphoma 2 associated X protein
BCL2 B-cell lymphoma 2
BrK Bradykinin
BSRF Brain stem reticular formation
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CAD Coronary artery disease
CEC Cardiac endothelial cell
CGRP Calcitonin gene-related peptide
CHD Congenital heart diseases
DCM Dilated cardiomyopathy
DMN Dorsal motor nucleus
DOAJ Directory of open access journals
DRG Dorsal root ganglia
EC Endothelial cell
EF Ejection fraction
eNOS Endothelial nitric oxide synthase
EPR Exercise pressor reflex
ERK1/2 Extracellular signal-regulated protein kinase 1/2
ERP Effective refractory period
FS Fractional shortening
H/R Hypoxia/reoxygenation
HF Heart failure
HFD High-fat diet
HFmrEF Heart failure with mid-range ejection fraction
HFpEF Heart failure with preserved ejection fraction
HFrEF Heart failure with reduced ejection fraction
HUVEC Human umbilical vein endothelial cell
I/R Ischemia/reperfusion
IPC Ischemic preconditioning
LRP1 LDL-related protein 1
MDPI Multidisciplinary Digital Publishing Institute
NA Nucleus ambiguus
NG Nodose ganglion
NGF Nerve growth factor
NTS Nucleus tractus solitarius
ONOO- Peroxynitrite
PACAP Pituitary adenylate cyclase-activating polypeptide
PCSK9 Proprotein convertase subtilisin/kexin type 9
PI3KI Phosphatidylinositol 3-kinase inhibitor
ROS Reactive oxygen species
RTX Resiniferatoxin
SERCA2a Sarco-endoplasmic reticulum Ca2+ ATPase 2a
SG Sympathetic ganglion
SHU Scoville Heat Unit
SP Substance P
SST Somatostatin
TAC Transverse aortic constriction
TNF Tumor necrosis factor alpha
TrkA Tropomyosin receptor kinase A
TRPV1 Transient receptor potential vanilloid type 1
VGCC Voltage-gated Ca2+ channel
VGSC Voltage-gated Na+ channel
VMSC Vascular smooth muscle cell
References
1. Jancsó, N. Desensitization with Capsaicin as a Tool for Studying the Function of Pain Receptors. In The
Pharmacology of Pain; Pergamon Press: Oxford, UK, 1968; pp. 33–55.
2. Julius, D. TRP channels and pain. Annu. Rev. Cell Dev. Biol. 2013, 29, 355–384. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 4472 17 of 23
3. Caterina, M.J.; Schumacher, M.A.; Tominaga, M.; Rosen, T.A.; Levine, J.D.; Julius, D. The capsaicin receptor:
A heat-activated ion channel in the pain pathway. Nature 1997, 389, 816–824. [CrossRef] [PubMed]
4. Maggi, C.A.; Patacchini, R.; Tramontana, M.; Amann, R.; Giuliani, S.; Santicioli, P. Similarities and differences
in the action of resiniferatoxin and capsaicin on central and peripheral endings of primary sensory neurons.
Neuroscience 1990, 37, 531–539. [CrossRef]
5. Jancsó, G.; Hökfelt, T.; Lundberg, J.M.; Kiraly, E.; Halász, N.; Nilsson, G.; Terenius, L.; Rehfeld, J.;
Steinbusch, H.; Verhofstad, A.; et al. Immunohistochemical Studies on the Effect of Capsaicin on Spinal and
Medullary Peptide and Monoamine Neurons Using Antisera to Substance P, gastrin/CCK, Somatostatin, VIP,
Enkephalin, Neurotensin and 5-hydroxytryptamine. J. Neurocytol. 1981, 10, 963–980. [CrossRef] [PubMed]
6. Jancso, G.; Such, G. Effects of capsaicin applied perineurally to the vagus nerve on cardiovascular and
respiratory functions in the cat. J. Physiol. 1983, 341, 359–370. [CrossRef]
7. Zahner, M.R.; Li, D.P.; Chen, S.R.; Pan, H.L. Cardiac vanilloid receptor 1-expressing afferent nerves and their
role in the cardiogenic sympathetic reflex in rats. J. Physiol 2003, 551, 515–523. [CrossRef]
8. Katona, M.; Boros, K.; Santha, P.; Ferdinandy, P.; Dux, M.; Jancso, G. Selective sensory denervation by
capsaicin aggravates adriamycin-induced cardiomyopathy in rats. Naunyn-Schmiedeberg’s Arch. Pharmacol.
2004, 370, 436–443. [CrossRef]
9. Mensah, G.A.; Roth, G.A.; Fuster, V. The Global Burden of Cardiovascular Diseases and Risk Factors: 2020
and Beyond. J. Am. Coll. Cardiol. 2019, 74, 2529–2532. [CrossRef]
10. Hinton, W.; McGovern, A.; Coyle, R.; Han, T.S.; Sharma, P.; Correa, A.; Ferreira, F.; de Lusignan, S. Incidence
and prevalence of cardiovascular disease in English primary care: A cross-sectional and follow-up study of
the Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC). BMJ Open 2018,
8, e020282. [CrossRef]
11. Bencsik, P.; Gomori, K.; Szabados, T.; Santha, P.; Helyes, Z.; Jancso, G.; Ferdinandy, P.; Gorbe, A. Myocardial
ischemia reperfusion injury and cardioprotection in the presence of sensory neuropathy: Therapeutic options.
Br. J. Pharmacol. 2020. [CrossRef]
12. Caterina, M.J.; Julius, D. The vanilloid receptor: A molecular gateway to the pain pathway. Annu. Rev. Neurosci.
2001, 24, 487–517. [CrossRef] [PubMed]
13. Cao, E.; Liao, M.; Cheng, Y.; Julius, D. TRPV1 structures in distinct conformations reveal activation
mechanisms. Nature 2013, 504, 113–118. [CrossRef]
14. Liao, M.; Cao, E.; Julius, D.; Cheng, Y. Structure of the TRPV1 ion channel determined by electron
cryo-microscopy. Nature 2013, 504, 107–112. [CrossRef]
15. Garcia-Martinez, C.; Morenilla-Palao, C.; Planells-Cases, R.; Merino, J.M.; Ferrer-Montiel, A. Identification of
an aspartic residue in the P-loop of the vanilloid receptor that modulates pore properties. J. Biol. Chem. 2000,
275, 32552–32558. [CrossRef]
16. Randhawa, P.K.; Jaggi, A.S. TRPV1 channels in cardiovascular system: A double edged sword? Int. J. Cardiol.
2017, 228, 103–113. [CrossRef] [PubMed]
17. Jung, J.; Hwang, S.W.; Kwak, J.; Lee, S.Y.; Kang, C.J.; Kim, W.B.; Kim, D.; Oh, U. Capsaicin binds to the
intracellular domain of the capsaicin-activated ion channel. J. Neurosci. 1999, 19, 529–538. [CrossRef]
[PubMed]
18. Miyake, T.; Shirakawa, H.; Nakagawa, T.; Kaneko, S. Activation of mitochondrial transient receptor potential
vanilloid 1 channel contributes to microglial migration. Glia 2015, 63, 1870–1882. [CrossRef]
19. Nagy, I.; Santha, P.; Jancso, G.; Urban, L. The role of the vanilloid (capsaicin) receptor (TRPV1) in physiology
and pathology. Eur. J. Pharmacol. 2004, 500, 351–369. [CrossRef]
20. Randhawa, P.K.; Jaggi, A.S. TRPV1 and TRPV4 channels: Potential therapeutic targets for ischemic
conditioning-induced cardioprotection. Eur. J. Pharmacol. 2015, 746, 180–185. [CrossRef] [PubMed]
21. Maggi, C.A.; Meli, A. The sensory-efferent function of capsaicin-sensitive sensory neurons. Gen. Pharmacol.
1988, 19, 1–43. [CrossRef]
22. Holzer, P. Local effector functions of capsaicin-sensitive sensory nerve endings: Involvement of tachykinins,
calcitonin gene-related peptide and other neuropeptides. Neuroscience 1988, 24, 739–768. [CrossRef]
23. Jancso, G.; Kiraly, E.; Such, G.; Joo, F.; Nagy, A. Neurotoxic effect of capsaicin in mammals. Acta Physiol. Hung.
1987, 69, 295–313. [PubMed]
Int. J. Mol. Sci. 2020, 21, 4472 18 of 23
24. Szolcsanyi, J.; Pinter, E.; Helyes, Z.; Oroszi, G.; Nemeth, J. Systemic anti-inflammatory effect induced by
counter-irritation through a local release of somatostatin from nociceptors. Br. J. Pharmacol. 1998, 125,
916–922. [CrossRef] [PubMed]
25. Pinter, E.; Helyes, Z.; Szolcsanyi, J. Inhibitory effect of somatostatin on inflammation and nociception.
Pharmacol. Ther. 2006, 112, 440–456. [CrossRef] [PubMed]
26. Szolcsanyi, J.; Pinter, E.; Helyes, Z.; Petho, G. Inhibition of the function of TRPV1-expressing nociceptive
sensory neurons by somatostatin 4 receptor agonism: Mechanism and therapeutical implications. Curr. Top.
Med. Chem. 2011, 11, 2253–2263. [CrossRef]
27. Santha, P.; Pierau, F.K.; Jancso, G. Evidence for an inhibition by endogenous galanin of neurogenic cutaneous
vasodilatation in the pigeon. Neurosci. Lett. 1998, 243, 101–104. [CrossRef]
28. Chen, Y.; Lyga, J. Brain-skin connection: Stress, inflammation and skin aging. Inflamm. Allergy-Drug Targets
2014, 13, 177–190. [CrossRef]
29. Dux, M.; Santha, P.; Jancso, G. The role of chemosensitive afferent nerves and TRP ion channels in the
pathomechanism of headaches. Pflug. Arch. Eur. J. Physiol. 2012, 464, 239–248. [CrossRef] [PubMed]
30. Jancso, G.; Obal, F., Jr.; Toth-Kasa, I.; Katona, M.; Husz, S. The modulation of cutaneous inflammatory
reactions by peptide-containing sensory nerves. Int. J. Tissue React. 1985, 7, 449–457.
31. Jancsó, G.; Katona, M.; Horváth, V.; Sántha, P.; Nagy, J. Sensory Nerves as Modulators of Cutaneous
Inflammatory Reactions in Health and Disease. In Neuroimmune Biology; Elsevier: Amsterdam,
The Netherlands, 2008; Volume 8, pp. 3–36.
32. Andrei, S.R.; Sinharoy, P.; Bratz, I.N.; Damron, D.S. TRPA1 is functionally co-expressed with TRPV1 in cardiac
muscle: Co-localization at z-discs, costameres and intercalated discs. Channels 2016, 10, 395–409. [CrossRef]
33. Zurborg, S.; Yurgionas, B.; Jira, J.A.; Caspani, O.; Heppenstall, P.A. Direct activation of the ion channel TRPA1
by Ca2+. Nat. Neurosci. 2007, 10, 277–279. [CrossRef] [PubMed]
34. Wang, Z.; Ye, D.; Ye, J.; Wang, M.; Liu, J.; Jiang, H.; Xu, Y.; Zhang, J.; Chen, J.; Wan, J. The TRPA1 Channel in
the Cardiovascular System: Promising Features and Challenges. Front. Pharmacol. 2019, 10, 1253. [CrossRef]
[PubMed]
35. Teofilo, T.M.; Duarte, G.P.; Borges, R.S.; Santos, A.A.; Magalhaes, P.J.C.; Lahlou, S. Stimulation of pulmonary
vagal C-fibers by trans-4-methyl-beta-nitrostyrene induces bradycardiac and depressor reflex in rats: Role of
vanilloid TRPV1 receptors. Eur. J. Pharmacol. 2019, 849, 154–159. [CrossRef] [PubMed]
36. Jancso, G.; Kiraly, E.; Jancso-Gabor, A. Direct evidence for an axonal site of action of capsaicin.
Naunyn-Schmiedeberg’s Arch. Pharmacol. 1980, 313, 91–94. [CrossRef] [PubMed]
37. Wang, X.L.; Tian, B.; Huang, Y.; Peng, X.Y.; Chen, L.H.; Li, J.C.; Liu, T. Hydrogen sulfide-induced itch requires
activation of Cav3.2 T-type calcium channel in mice. Sci. Rep. 2015, 5, 16768. [CrossRef] [PubMed]
38. Gamse, R.; Petsche, U.; Lembeck, F.; Jancso, G. Capsaicin applied to peripheral nerve inhibits axoplasmic
transport of substance P and somatostatin. Brain Res. 1982, 239, 447–462. [CrossRef]
39. Ainsworth, A.; Hall, P.; Wall, P.D.; Allt, G.; MacKenzie, M.L.; Gibson, S.; Polak, J.M. Effects of capsaicin
applied locally to adult peripheral nerve. II. Anatomy and enzyme and peptide chemistry of peripheral
nerve and spinal cord. Pain 1981, 11, 379–388. [CrossRef]
40. Ferdinandy, P.; Csont, T.; Csonka, C.; Torok, M.; Dux, M.; Nemeth, J.; Horvath, L.I.; Dux, L.; Szilvassy, Z.;
Jancso, G. Capsaicin-sensitive local sensory innervation is involved in pacing-induced preconditioning in rat
hearts: Role of nitric oxide and CGRP? Naunyn-Schmiedeberg’s Arch. Pharmacol. 1997, 356, 356–363. [CrossRef]
41. Wharton, J.; Gulbenkian, S.; Mulderry, P.K.; Ghatei, M.A.; McGregor, G.P.; Bloom, S.R.; Polak, J.M. Capsaicin
induces a depletion of calcitonin gene-related peptide (CGRP)-immunoreactive nerves in the cardiovascular
system of the guinea pig and rat. J. Auton. Nerv. Syst. 1986, 16, 289–309. [CrossRef]
42. Kallner, G.; Franco-Cereceda, A. Aggravation of myocardial infarction in the porcine heart by
capsaicin-induced depletion of calcitonin gene-related peptide (CGRP). J. Cardiovasc. Pharmacol. 1998,
32, 500–504. [CrossRef]
43. Zvara, A.; Bencsik, P.; Fodor, G.; Csont, T.; Hackler, L., Jr.; Dux, M.; Furst, S.; Jancso, G.; Puskas, L.G.;
Ferdinandy, P. Capsaicin-sensitive sensory neurons regulate myocardial function and gene expression pattern
of rat hearts: A DNA microarray study. FASEB J. 2006, 20, 160–162. [CrossRef] [PubMed]
44. Wu, Z.; He, E.Y.; Scott, G.I.; Ren, J. Alpha, beta-Unsaturated aldehyde pollutant acrolein suppresses
cardiomyocyte contractile function: Role of TRPV1 and oxidative stress. Environ. Toxicol. 2015, 30, 638–647.
[CrossRef] [PubMed]
Int. J. Mol. Sci. 2020, 21, 4472 19 of 23
45. Kun, J.; Helyes, Z.; Perkecz, A.; Ban, A.; Polgar, B.; Szolcsanyi, J.; Pinter, E. Effect of surgical and chemical
sensory denervation on non-neural expression of the transient receptor potential vanilloid 1 (TRPV1)
receptors in the rat. J. Mol. Neurosci. 2012, 48, 795–803. [CrossRef] [PubMed]
46. Kark, T.; Bagi, Z.; Lizanecz, E.; Pasztor, E.T.; Erdei, N.; Czikora, A.; Papp, Z.; Edes, I.; Porszasz, R.; Toth, A.
Tissue-specific regulation of microvascular diameter: Opposite functional roles of neuronal and smooth
muscle located vanilloid receptor-1. Mol. Pharmacol. 2008, 73, 1405–1412. [CrossRef]
47. Dux, M.; Santha, P.; Jancso, G. Capsaicin-sensitive neurogenic sensory vasodilatation in the dura mater of
the rat. J. Physiol. 2003, 552, 859–867. [CrossRef]
48. Porszasz, R.; Porkolab, A.; Ferencz, A.; Pataki, T.; Szilvassy, Z.; Szolcsanyi, J. Capsaicin-induced nonneural
vasoconstriction in canine mesenteric arteries. Eur. J. Pharmacol. 2002, 441, 173–175. [CrossRef]
49. Jancso, N.; Jancso-Gabor, A.; Szolcsanyi, J. The role of sensory nerve endings in neurogenic inflammation
induced in human skin and in the eye and paw of the rat. Br. J. Pharmacol. Chemother. 1968, 33, 32–41.
[CrossRef]
50. Jancso, G.; Kiraly, E.; Jancso-Gabor, A. Pharmacologically induced selective degeneration of chemosensitive
primary sensory neurones. Nature 1977, 270, 741–743. [CrossRef]
51. Rozsa, Z.; Jancso, G.; Varro, V. Possible involvement of capsaicin-sensitive sensory nerves in the regulation
of intestinal blood flow in the dog. Naunyn-Schmiedeberg’s Arch. Pharmacol. 1984, 326, 352–356. [CrossRef]
52. Toth, A.; Czikora, A.; Pasztor, E.T.; Dienes, B.; Bai, P.; Csernoch, L.; Rutkai, I.; Csato, V.; Manyine, I.S.;
Porszasz, R.; et al. Vanilloid receptor-1 (TRPV1) expression and function in the vasculature of the rat.
J. Histochem. Cytochem. 2014, 62, 129–144. [CrossRef]
53. Domoki, F.; Santha, P.; Bari, F.; Jancso, G. Perineural capsaicin treatment attenuates reactive hyperaemia in
the rat skin. Neurosci. Lett. 2003, 341, 127–130. [CrossRef]
54. Mahmmoud, Y.A.; Shattock, M.; Cornelius, F.; Pavlovic, D. Inhibition of K+ transport through Na+, K+-ATPase
by capsazepine: Role of membrane span 10 of the alpha-subunit in the modulation of ion gating. PLoS ONE
2014, 9, e96909. [CrossRef] [PubMed]
55. Docherty, R.J.; Yeats, J.C.; Piper, A.S. Capsazepine block of voltage-activated calcium channels in adult rat
dorsal root ganglion neurones in culture. Br. J. Pharmacol. 1997, 121, 1461–1467. [CrossRef] [PubMed]
56. Xiong, S.; Wang, P.; Ma, L.; Gao, P.; Gong, L.; Li, L.; Li, Q.; Sun, F.; Zhou, X.; He, H.; et al. Ameliorating
Endothelial Mitochondrial Dysfunction Restores Coronary Function via Transient Receptor Potential Vanilloid
1-Mediated Protein Kinase A/Uncoupling Protein 2 Pathway. Hypertension 2016, 67, 451–460. [CrossRef]
57. Ma, L.; Zhong, J.; Zhao, Z.; Luo, Z.; Ma, S.; Sun, J.; He, H.; Zhu, T.; Liu, D.; Zhu, Z.; et al. Activation of
TRPV1 reduces vascular lipid accumulation and attenuates atherosclerosis. Cardiovasc. Res. 2011, 92, 504–513.
[CrossRef]
58. Zhao, J.J.; Hu, Y.W.; Huang, C.; Ma, X.; Kang, C.M.; Zhang, Y.; Guo, F.X.; Lu, J.B.; Xiu, J.C.; Qiu, Y.R.; et al.
Dihydrocapsaicin suppresses proinflammatory cytokines expression by enhancing nuclear factor IA in a
NF-kappaB-dependent manner. Arch. Biochem. Biophys. 2016, 604, 27–35. [CrossRef]
59. Rollyson, W.D.; Stover, C.A.; Brown, K.C.; Perry, H.E.; Stevenson, C.D.; McNees, C.A.; Ball, J.G.;
Valentovic, M.A.; Dasgupta, P. Bioavailability of capsaicin and its implications for drug delivery.
J. Control. Release 2014, 196, 96–105. [CrossRef]
60. Kawada, T.; Suzuki, T.; Takahashi, M.; Iwai, K. Gastrointestinal absorption and metabolism of capsaicin and
dihydrocapsaicin in rats. Toxicol. Appl. Pharmacol. 1984, 72, 449–456. [CrossRef]
61. McCarty, M.F.; DiNicolantonio, J.J.; O’Keefe, J.H. Capsaicin may have important potential for promoting
vascular and metabolic health. Open Heart 2015, 2, e000262. [CrossRef]
62. Knuuti, J.; Wijns, W.; Saraste, A.; Capodanno, D.; Barbato, E.; Funck-Brentano, C.; Prescott, E.; Storey, R.F.;
Deaton, C.; Cuisset, T.; et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary
syndromes. Eur. Heart J. 2020, 41, 407–477. [CrossRef]
63. Nazarian-Samani, Z.; Sewell, R.D.E.; Rafieian-Kopaei, M. Inflammasome Signaling and other Factors
Implicated in Atherosclerosis Development and Progression. Curr. Pharm. Des. 2020. [CrossRef] [PubMed]
64. Bujak, J.K.; Kosmala, D.; Szopa, I.M.; Majchrzak, K.; Bednarczyk, P. Inflammation, Cancer and
Immunity-Implication of TRPV1 Channel. Front. Oncol. 2019, 9, 1087. [CrossRef] [PubMed]
65. Wang, Y.; Cui, L.; Xu, H.; Liu, S.; Zhu, F.; Yan, F.; Shen, S.; Zhu, M. TRPV1 agonism inhibits endothelial cell
inflammation via activation of eNOS/NO pathway. Atherosclerosis 2017, 260, 13–19. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2020, 21, 4472 20 of 23
66. Chen, K.S.; Chen, P.N.; Hsieh, Y.S.; Lin, C.Y.; Lee, Y.H.; Chu, S.C. Capsaicin protects endothelial cells and
macrophage against oxidized low-density lipoprotein-induced injury by direct antioxidant action. Chem. Biol.
Interact. 2015, 228, 35–45. [CrossRef]
67. Li, B.H.; Yin, Y.W.; Liu, Y.; Pi, Y.; Guo, L.; Cao, X.J.; Gao, C.Y.; Zhang, L.L.; Li, J.C. TRPV1 activation impedes
foam cell formation by inducing autophagy in oxLDL-treated vascular smooth muscle cells. Cell Death Dis.
2014, 5, e1182. [CrossRef]
68. Poonyachoti, S.; Kulkarni-Narla, A.; Brown, D.R. Chemical coding of neurons expressing delta- and
kappa-opioid receptor and type I vanilloid receptor immunoreactivities in the porcine ileum. Cell Tissue Res.
2002, 307, 23–33. [CrossRef]
69. Rizopoulos, T.; Papadaki-Petrou, H.; Assimakopoulou, M. Expression Profiling of the Transient Receptor
Potential Vanilloid (TRPV) Channels 1, 2, 3 and 4 in Mucosal Epithelium of Human Ulcerative Colitis. Cells
2018, 7, 61. [CrossRef] [PubMed]
70. Emini Veseli, B.; Perrotta, P.; De Meyer, G.R.A.; Roth, L.; Van der Donckt, C.; Martinet, W.; De Meyer, G.R.Y.
Animal models of atherosclerosis. Eur. J. Pharmacol. 2017, 816, 3–13. [CrossRef]
71. Wei, J.; Ching, L.C.; Zhao, J.F.; Shyue, S.K.; Lee, H.F.; Kou, Y.R.; Lee, T.S. Essential role of transient receptor
potential vanilloid type 1 in evodiamine-mediated protection against atherosclerosis. Acta Physiol. 2013, 207,
299–307. [CrossRef]
72. Gao, W.; Sun, Y.; Cai, M.; Zhao, Y.; Cao, W.; Liu, Z.; Cui, G.; Tang, B. Copper sulfide nanoparticles as a
photothermal switch for TRPV1 signaling to attenuate atherosclerosis. Nat. Commun. 2018, 9, 231. [CrossRef]
73. Ferdinandy, P.; Hausenloy, D.J.; Heusch, G.; Baxter, G.F.; Schulz, R. Interaction of risk factors,
comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning,
postconditioning, and remote conditioning. Pharmacol. Rev. 2014, 66, 1142–1174. [CrossRef] [PubMed]
74. Ferdinandy, P.; Schulz, R.; Baxter, G.F. Interaction of cardiovascular risk factors with myocardial
ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol. Rev. 2007, 59, 418–458.
[CrossRef] [PubMed]
75. Ustinova, E.E.; Bergren, D.; Schultz, H.D. Neuropeptide depletion impairs postischemic recovery of the
isolated rat heart: Role of substance P. Cardiovasc. Res. 1995, 30, 55–63. [CrossRef]
76. Zhang, R.L.; Guo, Z.; Wang, L.L.; Wu, J. Degeneration of capsaicin sensitive sensory nerves enhances
myocardial injury in acute myocardial infarction in rats. Int. J. Cardiol. 2012, 160, 41–47. [CrossRef]
77. Sogut, O.; Kaya, H.; Gokdemir, M.T.; Sezen, Y. Acute myocardial infarction and coronary vasospasm
associated with the ingestion of cayenne pepper pills in a 25-year-old male. Int. J. Emerg. Med. 2012, 5, 5.
[CrossRef]
78. Sayin, M.R.; Karabag, T.; Dogan, S.M.; Akpinar, I.; Aydin, M. A case of acute myocardial infarction due to the
use of cayenne pepper pills. Wien. Klin. Wochenschr. 2012, 124, 285–287. [CrossRef]
79. Sun, Z.; Han, J.; Zhao, W.; Zhang, Y.; Wang, S.; Ye, L.; Liu, T.; Zheng, L. TRPV1 activation exacerbates
hypoxia/reoxygenation-induced apoptosis in H9C2 cells via calcium overload and mitochondrial dysfunction.
Int. J. Mol. Sci. 2014, 15, 18362–18380. [CrossRef]
80. Jiang, X.X.; Liu, G.Y.; Lei, H.; Li, Z.L.; Feng, Q.P.; Huang, W. Activation of transient receptor potential
vanilloid 1 protects the heart against apoptosis in ischemia/reperfusion injury through upregulating the
PI3K/Akt signaling pathway. Int. J. Mol. Med. 2018, 41, 1724–1730. [CrossRef]
81. Wang, L.; Wang, D.H. TRPV1 gene knockout impairs postischemic recovery in isolated perfused heart in
mice. Circulation 2005, 112, 3617–3623. [CrossRef]
82. Li, Y.J.; Xiao, Z.S.; Peng, C.F.; Deng, H.W. Calcitonin gene-related peptide-induced preconditioning protects
against ischemia-reperfusion injury in isolated rat hearts. Eur. J. Pharmacol. 1996, 311, 163–167. [CrossRef]
83. Priestley, J.V.; Michael, G.J.; Averill, S.; Liu, M.; Willmott, N. Regulation of nociceptive neurons by nerve
growth factor and glial cell line derived neurotrophic factor. Can. J. Physiol. Pharmacol. 2002, 80, 495–505.
[CrossRef] [PubMed]
84. Cheng, X.Y.; Chen, C.; He, S.F.; Huang, C.X.; Zhang, L.; Chen, Z.W.; Zhang, Y. Spinal NGF induces
anti-intrathecal opioid-initiated cardioprotective effect via regulation of TRPV1 expression. Eur. J. Pharmacol.
2019, 844, 145–155. [CrossRef] [PubMed]
85. Dou, M.; Ma, Z.; Cheng, X.; Zou, G.; Xu, Y.; Huang, C.; Xiong, W.; He, S.; Zhang, Y.
Intrathecal lentivirus-mediated RNA interference targeting nerve growth factor attenuates myocardial
ischaemia-reperfusion injury in rat. Br. J. Anaesth. 2019, 123, 439–449. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2020, 21, 4472 21 of 23
86. Zheng, L.R.; Zhang, Y.Y.; Han, J.; Sun, Z.W.; Zhou, S.X.; Zhao, W.T.; Wang, L.H. Nerve growth factor
rescues diabetic mice heart after ischemia/reperfusion injury via up-regulation of the TRPV1 receptor.
J. Diabetes Complicat. 2015, 29, 323–328. [CrossRef] [PubMed]
87. Al-Awar, A.; Almasi, N.; Szabo, R.; Takacs, I.; Murlasits, Z.; Szucs, G.; Torok, S.; Posa, A.; Varga, C.; Kupai, K.
Novel Potentials of the DPP-4 Inhibitor Sitagliptin against Ischemia-Reperfusion (I/R) Injury in Rat Ex-Vivo
Heart Model. Int. J. Mol. Sci. 2018, 19, 3226. [CrossRef]
88. Heymann, H.M.; Wu, Y.; Lu, Y.; Qvit, N.; Gross, G.J.; Gross, E.R. Transient receptor potential vanilloid 1
inhibitors block laparotomy- and opioid-induced infarct size reduction in rats. Br. J. Pharmacol. 2017, 174,
4826–4835. [CrossRef]
89. Song, Q.J.; Li, Y.J.; Deng, H.W. Cardioprotective effect of bradykinin-induced preconditioning mediated by
calcitonin gene-related peptide in isolated rat heart. Zhongguo Yao Li Xue Bao 1999, 20, 162–166.
90. Peng, J.; Xiao, J.; Ye, F.; Deng, H.W.; Li, Y.J. Inhibition of cardiac tumor necrosis factor-alpha production by
calcitonin gene-related peptide-mediated ischemic preconditioning in isolated rat hearts. Eur. J. Pharmacol.
2000, 407, 303–308. [CrossRef]
91. Luo, D.; Deng, P.Y.; Ye, F.; Peng, W.J.; Deng, H.W.; Li, Y.J. Delayed preconditioning by cardiac ischemia
involves endogenous calcitonin gene-related peptide via the nitric oxide pathway. Eur. J. Pharmacol. 2004,
502, 135–141. [CrossRef]
92. He, S.Y.; Deng, H.W.; Li, Y.J. Monophosphoryl lipid A-induced delayed preconditioning is mediated by
calcitonin gene-related peptide. Eur. J. Pharmacol. 2001, 420, 143–149. [CrossRef]
93. Chen, K.; Yu, J.; Wang, Q.; Wu, L.; Liu, X.; Wong, G.T.C.; Lu, Y. The timing of propofol administration affects
the effectiveness of remote ischemic preconditioning induced cardioprotection in rats. J. Cell Biochem. 2020.
[CrossRef] [PubMed]
94. Gao, Y.; Song, J.; Chen, H.; Cao, C.; Lee, C. TRPV1 activation is involved in the cardioprotection of remote
limb ischemic postconditioning in ischemia-reperfusion injury rats. Biochem. Biophys. Res. Commun. 2015,
463, 1034–1039. [CrossRef] [PubMed]
95. Ren, J.Y.; Song, J.X.; Lu, M.Y.; Chen, H. Cardioprotection by ischemic postconditioning is lost in isolated
perfused heart from diabetic rats: Involvement of transient receptor potential vanilloid 1, calcitonin
gene-related peptide and substance P. Regul. Pept. 2011, 169, 49–57. [CrossRef] [PubMed]
96. Zhong, B.; Wang, D.H. N-oleoyldopamine, a novel endogenous capsaicin-like lipid, protects the heart
against ischemia-reperfusion injury via activation of TRPV1. Am. J. Physiol. Heart Circ. Physiol. 2008, 295,
H728–H735. [CrossRef]
97. Ferdinandy, P.; Jancsó, G. Capsaicin-Sensitive Sensory Nerves in Myocardial Ischemia-Reperfusion Injury
and Ischemic Stress Adaptation. Role of Nitric Oxide and Calcitonin Gene-Related Peptide. In Neurogenic
Inflammation in Health and Disease; Elsevier: Amsterdam, The Netherlands, 2009; pp. 267–288.
98. Qi, Y.; Qi, Z.; Li, Z.; Wong, C.K.; So, C.; Lo, I.C.; Huang, Y.; Yao, X.; Tsang, S.Y. Role of TRPV1 in the
Differentiation of Mouse Embryonic Stem Cells into Cardiomyocytes. PLoS ONE 2015, 10, e0133211.
[CrossRef]
99. Hajouli, S.; Ludhwani, D. Heart Failure and Ejection Fraction; StatPearls: Treasure Island, FL, USA, 2020.
100. Ponikowski, P.; Voors, A.A.; Anker, S.D.; Bueno, H.; Cleland, J.G.F.; Coats, A.J.S.; Falk, V.;
Gonzalez-Juanatey, J.R.; Harjola, V.P.; Jankowska, E.A.; et al. 2016 ESC Guidelines for the diagnosis
and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and
chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of
the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2016, 37, 2129–2200. [CrossRef]
101. Smith, S.A.; Williams, M.A.; Mitchell, J.H.; Mammen, P.P.; Garry, M.G. The capsaicin-sensitive afferent neuron
in skeletal muscle is abnormal in heart failure. Circulation 2005, 111, 2056–2065. [CrossRef]
102. Wang, H.J.; Wang, W.; Cornish, K.G.; Rozanski, G.J.; Zucker, I.H. Cardiac sympathetic afferent denervation
attenuates cardiac remodeling and improves cardiovascular dysfunction in rats with heart failure.
Hypertension 2014, 64, 745–755. [CrossRef]
103. Wang, D.; Wu, Y.; Chen, Y.; Wang, A.; Lv, K.; Kong, X.; He, Y.; Hu, N. Focal selective chemo-ablation of spinal
cardiac afferent nerve by resiniferatoxin protects the heart from pressure overload-induced hypertrophy.
Biomed. Pharmacother. 2019, 109, 377–385. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 4472 22 of 23
104. Bencsik, P.; Kiss, K.; Agg, B.; Baan, J.A.; Agoston, G.; Varga, A.; Gomori, K.; Mendler, L.; Farago, N.;
Zvara, A.; et al. Sensory Neuropathy Affects Cardiac miRNA Expression Network Targeting IGF-1, SLC2a-12,
EIF-4e, and ULK-2 mRNAs. Int. J. Mol. Sci. 2019, 20, 991. [CrossRef]
105. Bencsik, P.; Kupai, K.; Giricz, Z.; Gorbe, A.; Huliak, I.; Furst, S.; Dux, L.; Csont, T.; Jancso, G.; Ferdinandy, P.
Cardiac capsaicin-sensitive sensory nerves regulate myocardial relaxation via S-nitrosylation of SERCA: Role
of peroxynitrite. Br. J. Pharmacol. 2008, 153, 488–496. [CrossRef] [PubMed]
106. Huang, W.; Rubinstein, J.; Prieto, A.R.; Wang, D.H. Enhanced postmyocardial infarction fibrosis via
stimulation of the transforming growth factor-beta-Smad2 signaling pathway: Role of transient receptor
potential vanilloid type 1 channels. J. Hypertens. 2010, 28, 367–376. [CrossRef] [PubMed]
107. Lang, H.; Li, Q.; Yu, H.; Li, P.; Lu, Z.; Xiong, S.; Yang, T.; Zhao, Y.; Huang, X.; Gao, P.; et al. Activation of
TRPV1 attenuates high salt-induced cardiac hypertrophy through improvement of mitochondrial function.
Br. J. Pharmacol. 2015, 172, 5548–5558. [CrossRef] [PubMed]
108. Buckley, C.L.; Stokes, A.J. Mice lacking functional TRPV1 are protected from pressure overload cardiac
hypertrophy. Channels 2011, 5, 367–374. [CrossRef]
109. Zhong, B.; Rubinstein, J.; Ma, S.; Wang, D.H. Genetic ablation of TRPV1 exacerbates pressure overload-induced
cardiac hypertrophy. Biomed. Pharmacother. 2018, 99, 261–270. [CrossRef]
110. Wang, Q.; Ma, S.; Li, D.; Zhang, Y.; Tang, B.; Qiu, C.; Yang, Y.; Yang, D. Dietary capsaicin ameliorates pressure
overload-induced cardiac hypertrophy and fibrosis through the transient receptor potential vanilloid type 1.
Am. J. Hypertens. 2014, 27, 1521–1529. [CrossRef]
111. Fouad, A.A.; Yacoubi, M.T. Mechanisms underlying the protective effect of eugenol in rats with acute
doxorubicin cardiotoxicity. Arch. Pharm. Res. 2011, 34, 821–828. [CrossRef]
112. Ge, W.; Yuan, M.; Ceylan, A.F.; Wang, X.; Ren, J. Mitochondrial aldehyde dehydrogenase protects against
doxorubicin cardiotoxicity through a transient receptor potential channel vanilloid 1-mediated mechanism.
Biochim. Biophys. Acta 2016, 1862, 622–634. [CrossRef]
113. Chen, J.; Hamers, A.J.P.; Finsterbusch, M.; Massimo, G.; Zafar, M.; Corder, R.; Colas, R.A.; Dalli, J.;
Thiemermann, C.; Ahluwalia, A. Endogenously generated arachidonate-derived ligands for TRPV1 induce
cardiac protection in sepsis. FASEB J. 2018, 32, 3816–3831. [CrossRef]
114. Csont, T.; Csonka, C.; Kovacs, P.; Jancso, G.; Ferdinandy, P. Capsaicin-sensitive sensory neurons regulate
myocardial nitric oxide and cGMP signaling. Eur. J. Pharmacol. 2003, 476, 107–113. [CrossRef]
115. Wang, H.J.; Li, Y.L.; Gao, L.; Zucker, I.H.; Wang, W. Alteration in skeletal muscle afferents in rats with chronic
heart failure. J. Physiol. 2010, 588, 5033–5047. [CrossRef] [PubMed]
116. Dragun, M.; Gazova, A.; Kyselovic, J.; Hulman, M.; Matus, M. TRP Channels Expression Profile in Human
End-Stage Heart Failure. Medicina 2019, 55, 380. [CrossRef] [PubMed]
117. Wang, Y.; Wang, D.H. A novel mechanism contributing to development of Dahl salt-sensitive hypertension:
Role of the transient receptor potential vanilloid type 1. Hypertension 2006, 47, 609–614. [CrossRef] [PubMed]
118. Boros, K.; Jancso, G.; Dux, M.; Fekecs, Z.; Bencsik, P.; Oszlacs, O.; Katona, M.; Ferdinandy, P.; Nogradi, A.;
Santha, P. Multiple impairments of cutaneous nociceptor function induced by cardiotoxic doses of Adriamycin
in the rat. Naunyn-Schmiedeberg’s Arch. Pharmacol. 2016, 389, 1009–1020. [CrossRef]
119. Choudhary, R.; Mishra, K.P.; Subramanyam, C. Interrelations between oxidative stress and calcineurin in the
attenuation of cardiac apoptosis by eugenol. Mol. Cell Biochem. 2006, 283, 115–122. [CrossRef]
120. Ma, H.; Guo, R.; Yu, L.; Zhang, Y.; Ren, J. Aldehyde dehydrogenase 2 (ALDH2) rescues myocardial
ischaemia/reperfusion injury: Role of autophagy paradox and toxic aldehyde. Eur. Heart J. 2011, 32,
1025–1038. [CrossRef]
121. Janse, M.J.; Wit, A.L. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial
ischemia and infarction. Physiol. Rev. 1989, 69, 1049–1169. [CrossRef]
122. Nattel, S.; Maguy, A.; Le Bouter, S.; Yeh, Y.H. Arrhythmogenic ion-channel remodeling in the heart: Heart
failure, myocardial infarction, and atrial fibrillation. Physiol. Rev. 2007, 87, 425–456. [CrossRef]
123. Lip, G.Y.; Heinzel, F.R.; Gaita, F.; Juanatey, J.R.; Le Heuzey, J.Y.; Potpara, T.; Svendsen, J.H.; Vos, M.A.;
Anker, S.D.; Coats, A.J.; et al. European Heart Rhythm Association/Heart Failure Association joint consensus
document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart
Rhythm Society. Europace 2016, 18, 12–36. [CrossRef]
124. Sewell, W.H.; Koth, D.R.; Huggins, C.E. Ventricular fibrillation in dogs after sudden return of flow to the
coronary artery. Surgery 1955, 38, 1050–1053.
Int. J. Mol. Sci. 2020, 21, 4472 23 of 23
125. Krumholz, H.M.; Goldberger, A.L. Reperfusion arrhythmias after thrombolysis. Electrophysiologic tempest,
or much ado about nothing. Chest 1991, 99, 135S–140S. [CrossRef] [PubMed]
126. Castle, N.A. Differential inhibition of potassium currents in rat ventricular myocytes by capsaicin.
Cardiovasc. Res. 1992, 26, 1137–1144. [CrossRef] [PubMed]
127. D’Alonzo, A.J.; Grover, G.J.; Darbenzio, R.B.; Hess, T.A.; Sleph, P.G.; Dzwonczyk, S.; Zhu, J.L.; Sewter, J.C.
In vitro effects of capsaicin: Antiarrhythmic and antiischemic activity. Eur. J. Pharmacol. 1995, 272, 269–278.
[CrossRef]
128. Wu, Y.; Hu, Z.; Wang, D.; Lv, K.; Hu, N. Resiniferatoxin reduces ventricular arrhythmias in heart failure via
selectively blunting cardiac sympathetic afferent projection into spinal cord in rats. Eur. J. Pharmacol. 2020,
867, 172836. [CrossRef] [PubMed]
129. Yoshie, K.; Rajendran, P.S.; Massoud, L.; Mistry, J.; Swid, M.A.; Wu, X.; Sallam, T.; Zhang, R.; Goldhaber, J.I.;
Salavatian, S.; et al. Cardiac TRPV1 afferent signaling promotes arrhythmogenic ventricular remodeling
after myocardial infarction. JCI Insight 2020, 5. [CrossRef] [PubMed]
130. Xu, S.; Xu, Y.; Cheng, X.; Huang, C.; Pan, Y.; Jin, S.; Xiong, W.; Zhang, L.; He, S.; Zhang, Y. Inhibition
of DRG-TRPV1 upregulation in myocardial ischemia contributes to exogenous cardioprotection. J. Mol.
Cell Cardiol. 2020, 138, 175–184. [CrossRef]
131. Horton, J.S.; Shiraishi, T.; Alfulaij, N.; Small-Howard, A.L.; Turner, H.C.; Kurokawa, T.; Mori, Y.; Stokes, A.J.
TRPV1 is a component of the atrial natriuretic signaling complex, and using orally delivered antagonists,
presents a valid therapeutic target in the longitudinal reversal and treatment of cardiac hypertrophy and
heart failure. Channels 2019, 13, 1–16. [CrossRef]
132. Ambrosy, A.P.; Fonarow, G.C.; Butler, J.; Chioncel, O.; Greene, S.J.; Vaduganathan, M.; Nodari, S.; Lam, C.S.P.;
Sato, N.; Shah, A.N.; et al. The global health and economic burden of hospitalizations for heart failure:
Lessons learned from hospitalized heart failure registries. J. Am. Coll. Cardiol. 2014, 63, 1123–1133. [CrossRef]
133. Linz, D.; Elliott, A.D.; Hohl, M.; Malik, V.; Schotten, U.; Dobrev, D.; Nattel, S.; Bohm, M.; Floras, J.; Lau, D.H.;
et al. Role of autonomic nervous system in atrial fibrillation. Int. J. Cardiol. 2019, 287, 181–188. [CrossRef]
134. Ghias, M.; Scherlag, B.J.; Lu, Z.; Niu, G.; Moers, A.; Jackman, W.M.; Lazzara, R.; Po, S.S. The role of
ganglionated plexi in apnea-related atrial fibrillation. J. Am. Coll. Cardiol. 2009, 54, 2075–2083. [CrossRef]
135. Tavares, L.; Rodriguez-Manero, M.; Kreidieh, B.; Ibarra-Cortez, S.H.; Chen, J.; Wang, S.; Markovits, J.;
Barrios, R.; Valderrabano, M. Cardiac Afferent Denervation Abolishes Ganglionated Plexi and Sympathetic
Responses to Apnea: Implications for Atrial Fibrillation. Circ. Arrhythmia Electrophysiol. 2019, 12, e006942.
[CrossRef] [PubMed]
136. Duzen, I.V.; Yavuz, F.; Vuruskan, E.; Saracoglu, E.; Poyraz, F.; Goksuluk, H.; Candemir, B.; Demiryurek, S.
Leukocyte TRP channel gene expressions in patients with non-valvular atrial fibrillation. Sci. Rep. 2017, 7,
9272. [CrossRef] [PubMed]
137. Gutierrez, A.; Van Wagoner, D.R. Oxidant and Inflammatory Mechanisms and Targeted Therapy in Atrial
Fibrillation: An Update. J. Cardiovasc. Pharmacol. 2015, 66, 523–529. [CrossRef] [PubMed]
138. Varro, A.; Lathrop, D.A.; Hester, S.B.; Nanasi, P.P.; Papp, J.G. Ionic currents and action potentials in rabbit,
rat, and guinea pig ventricular myocytes. Basic Res. Cardiol. 1993, 88, 93–102. [CrossRef]
139. Baczko, I.; Jost, N.; Virag, L.; Bosze, Z.; Varro, A. Rabbit models as tools for preclinical cardiac
electrophysiological safety testing: Importance of repolarization reserve. Prog. Biophys. Mol. Biol.
2016, 121, 157–168. [CrossRef] [PubMed]
140. Williams, K.; Carson, J.; Lo, C. Genetics of Congenital Heart Disease. Biomolecules 2019, 9, 879. [CrossRef]
141. Botto, L.D.; Panichello, J.D.; Browne, M.L.; Krikov, S.; Feldkamp, M.L.; Lammer, E.; Shaw, G.M.; National
Birth Defects Prevention, S. Congenital heart defects after maternal fever. Am. J. Obstet. Gynecol. 2014, 210,
359.e1. [CrossRef]
142. Hutson, M.R.; Keyte, A.L.; Hernandez-Morales, M.; Gibbs, E.; Kupchinsky, Z.A.; Argyridis, I.; Erwin, K.N.;
Pegram, K.; Kneifel, M.; Rosenberg, P.B.; et al. Temperature-activated ion channels in neural crest cells confer
maternal fever-associated birth defects. Sci. Signal. 2017, 10. [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
